Rfxank-KO Mouse
一般名
Rfxank-KO
製品ID
S-KO-04083
背景情報
C57BL/6JCya
系統ID
KOCMP-19727-Rfxank-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Rfxank-KO Mouse（カタログ番号S-KO-04083）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Rfxank-KO
系統ID
KOCMP-19727-Rfxank-B6J-VA
遺伝子名
製品ID
S-KO-04083
遺伝子別名
Tvl1
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 8
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000212320
NCBIトランスクリプトID
NM_011266
ターゲット領域
Exon 3~6
有効領域の大きさ
~2.0 kb
遺伝子研究の概要
RFXANK, the regulatory factor X-associated ankyrin-containing protein, is a crucial subunit of the heterotrimeric RFX complex. This complex is involved in the regulation of the transcription of major histocompatibility complex class II (MHC II) molecules in antigen-presenting cells, which is essential for the proper functioning of the immune system [3,5,6,7,8,9]. It also interacts with RFX7 and caspase-2, potentially playing roles in natural killer cell-mediated immunity, neuron development, and MHC II gene regulation [2,4].
Mutations in the RFXANK gene account for over 70% of known patients with MHC II deficiency worldwide. Homozygous loss-of-function mutations in RFXANK can cause bare lymphocyte syndrome (BLS) type II, and the associated phenotype has been expanded to include progressive neurodegenerative disease, with MRI showing global cerebral and cerebellar atrophy [1,3,6]. Patients with RFXANK mutations often present with later onset and diagnosis compared to those with RFX5 mutations in MHC-II deficiency [5].
In conclusion, RFXANK is essential for the regulation of MHC II molecule transcription, playing a key role in immune function. The discovery of its association with neurodegenerative disease through studies of patients with RFXANK mutations broadens our understanding of its functions. Understanding RFXANK's role can potentially aid in early diagnosis, prognosis refinement, and treatment strategies for MHC-II deficiency-related diseases [1,3,5].
References:
1. Alharby, Essa, Obaid, Mona, Elamin, Mohammed A O, Alasmari, Ali, Almontashiri, Naif A M. 2021. Progressive Ataxia and Neurologic Regression in RFXANK-Associated Bare Lymphocyte Syndrome. In Neurology. Genetics, 7, e586. doi:10.1212/NXG.0000000000000586. https://pubmed.ncbi.nlm.nih.gov/33855173/
2. Gao, Jun, Xu, Chao. 2019. Structural basis for the recognition of RFX7 by ANKRA2 and RFXANK. In Biochemical and biophysical research communications, 523, 263-266. doi:10.1016/j.bbrc.2019.12.059. https://pubmed.ncbi.nlm.nih.gov/31864703/
3. Cai, Yu Qing, Zhang, HangHu, Wang, Xiang Zhi, Shu, YingYing, Tang, Lan Fang. 2020. A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review. In Open forum infectious diseases, 7, ofaa314. doi:10.1093/ofid/ofaa314. https://pubmed.ncbi.nlm.nih.gov/32875002/
4. Forsberg, Jeremy, Li, Xinge, Akpinar, Birce, Zhivotovsky, Boris, Olsson, Magnus. 2018. A caspase-2-RFXANK interaction and its implication for MHC class II expression. In Cell death & disease, 9, 80. doi:10.1038/s41419-017-0144-y. https://pubmed.ncbi.nlm.nih.gov/29362422/
5. Gulec Koksal, Zeynep, Bilgic Eltan, Sevgi, Topyildiz, Ezgi, Karakoc Aydiner, Elif, Baris, Safa. 2024. MHC Class II Deficiency: Clinical, Immunological, and Genetic Insights in a Large Multicenter Cohort. In The journal of allergy and clinical immunology. In practice, 12, 2490-2502.e6. doi:10.1016/j.jaip.2024.06.046. https://pubmed.ncbi.nlm.nih.gov/38996837/
6. Abolnezhadian, Farhad, Dehghani, Razieh, Dehnavi, Sajad, Khodadadi, Ali, Shohan, Mojtaba. . A novel mutation in RFXANK gene and low B cell count in a patient with MHC class II deficiency: a case report. In Immunologic research, 68, 225-231. doi:10.1007/s12026-020-09141-9. https://pubmed.ncbi.nlm.nih.gov/32578129/
7. Mousavi Khorshidi, Mohadese Sadat, Seeleuthner, Yoann, Chavoshzadeh, Zahra, Shahrooei, Mohammad, Parvaneh, Nima. 2023. Clinical, Immunological, and Genetic Findings in Iranian Patients with MHC-II Deficiency: Confirmation of c.162delG RFXANK Founder Mutation in the Iranian Population. In Journal of clinical immunology, 43, 1941-1952. doi:10.1007/s10875-023-01562-z. https://pubmed.ncbi.nlm.nih.gov/37584719/
8. Wiszniewski, Wojciech, Fondaneche, Marie-Claude, Louise-Plence, Pascale, Fischer, Alain, Lisowska-Grospierre, Barbara. 2003. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. In Immunogenetics, 54, 747-55. doi:. https://pubmed.ncbi.nlm.nih.gov/12618906/
9. Chakraborty, Madhumita, Sengupta, Amitava, Bhattacharya, Dipankar, Banerjee, Subrata, Chakrabarti, Abhijit. 2010. DNA binding domain of RFX5: interactions with X-box DNA and RFXANK. In Biochimica et biophysica acta, 1804, 2016-24. doi:10.1016/j.bbapap.2010.07.009. https://pubmed.ncbi.nlm.nih.gov/20637319/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。